AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for January 16, 2019 meeting

IV. Secretary’s report

V. Old Business
   Proposed protocol for dupilumab (Dupixent®).
   Input from dermatologists, Dr. Linda S. Marcus and Dr. Booth Durham (DSNJ)

VI. New Business
   A. Proposed protocol for calcitonin gene-related peptide (CGRP) inhibitors
   B. Proposed protocol for gout products

VII. Newsletter on medication assisted treatment (MAT) products

VIII. Informational Highlight/Reports
   A. Report on major changes in top drugs ranking for April 2019 meeting
      B. Informational Highlights/Reports
         1. DXC Technology/NJ HMO 4th Quarter 2018 Prior Authorization Report
         2. Summary of DURB Action Items
         3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
            (b) Physician-administered/Antiviral drugs by amount paid
         4. Medication information:
            (a) FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan
            (b) Non-vitamin K oral anticoagulants (NOACs) Now Recommended Over Warfarin to Prevent A-Fib-related Stroke
            (c) Benzodiazepine use may increase pneumonia risk
            (d) Acetaminophen undetectable in more than half of related drug-induced liver injury (DILI)
            (e) FDA warns of Higher Risk for Death With Gout Drug Febuxostat (Uloric)
            (f) Hep C Infection May Be on the Rise Among Men Using PrEP

IX. Referenced Material
   A. Proposed protocol for dupilumab (Dupixent®)